Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Deferred Revenue (2016 - 2018)

Neurocrine Biosciences (NBIX) has disclosed Current Deferred Revenue for 9 consecutive years, with $731000.0 as the latest value for Q1 2018.

  • For the quarter ending Q1 2018, Current Deferred Revenue fell 79.42% year-over-year to $731000.0, compared with a TTM value of $731000.0 through Mar 2018, down 79.42%, and an annual FY2017 reading of $731000.0, down 79.27% over the prior year.
  • Current Deferred Revenue was $731000.0 for Q1 2018 at Neurocrine Biosciences, roughly flat from $731000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $10.2 million in Q1 2015 and bottomed at $85000.0 in Q3 2014.
  • Average Current Deferred Revenue over 5 years is $3.2 million, with a median of $3.3 million recorded in 2014.
  • The sharpest move saw Current Deferred Revenue plummeted 97.35% in 2014, then soared 1663.96% in 2016.
  • Year by year, Current Deferred Revenue stood at $3.3 million in 2014, then surged by 206.86% to $10.2 million in 2015, then plummeted by 65.43% to $3.5 million in 2016, then plummeted by 79.27% to $731000.0 in 2017, then changed by 0.0% to $731000.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for NBIX at $731000.0 in Q1 2018, $731000.0 in Q4 2017, and $731000.0 in Q3 2017.